Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer

  • Authors:
    • Keiichiro Nakamura
    • Fernando Abarzua
    • Junichi Kodama
    • Atsushi Hongo
    • Yasutomo Nasu
    • Hiromi Kumon
    • Yuji Hiramatsu
  • View Affiliations

  • Published online on: February 1, 2009     https://doi.org/10.3892/ijo_00000157
  • Pages: 345-353
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In light of the poor prognosis for ovarian cancer, research continues for innovative and efficacious treatment modalities. It is now widely accepted that new approaches for the treatment of ovarian cancers are pivotal to further improve the prognosis of this disease. We investigated the role of HAI-1 and HAI-2, and evaluated their clinical importance in ovarian cancer. The distribution of cases that scored positive for each of the biological parameters examined was correlated with HAI-1 and HAI-2 expression status obtained by immunohistochemistry. There was a significant correlation between HAI-2 expression and stage (p=0.031), amount of ascites (p=0.002) and diameter of residual tumor (p=0.034). HAI-1 expression was a significant associated with stage (p=0.040). Furthermore, the low HAI-1 and HAI-2 expression was a significant predictor for poor prognosis when compared with high HAI-1 and HAI-2 expression (disease-free survival rate; p=0.031 and p=0.003, overall survival rate; p=0.048 and p=0.001). Therefore, we investigated biological functions and effects of HAI-1 and HAI-2 using OVCAR-3 ovarian cancer cell lines. HAI-1 and HAI-2 show potential inhibitory effects mediated by reduction of matriptase and hepsin expression which leads to apoptosis through increasing the level of Bak and reducing the level of Bcl-2 on ovarian cancer. These findings indicate that low HAI-1 and HAI-2 expression in ovarian cancer may be associated with poor prognosis. HAI-1 and HAI-2 could be considered a therapeutic target for treatment approaches in ovarian cancer.

Related Articles

Journal Cover

February 2009
Volume 34 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakamura, K., Abarzua, F., Kodama, J., Hongo, A., Nasu, Y., Kumon, H., & Hiramatsu, Y. (2009). Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. International Journal of Oncology, 34, 345-353. https://doi.org/10.3892/ijo_00000157
MLA
Nakamura, K., Abarzua, F., Kodama, J., Hongo, A., Nasu, Y., Kumon, H., Hiramatsu, Y."Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer". International Journal of Oncology 34.2 (2009): 345-353.
Chicago
Nakamura, K., Abarzua, F., Kodama, J., Hongo, A., Nasu, Y., Kumon, H., Hiramatsu, Y."Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer". International Journal of Oncology 34, no. 2 (2009): 345-353. https://doi.org/10.3892/ijo_00000157